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Abstract
The common co-existence of cough and gastroesophageal reflux disease (GORD) is well
established. However, ascertaining cause and effect is more difficult for many reasons that include
occurrence by chance of two common symptoms, the changing definition of GORD, equipment
limitations and the lack of randomised controlled trials. Given these difficulties, it is not surprising
that there is disparity of opinion between respiratory and gastroenterology society guidelines on
the link between GORD and chronic cough. This commentary explores of these issues.
Background
The first guideline on the management of cough champi-
oned by Irwin [1] made a significant positive impact. Not
surprisingly other guidelines on chronic cough [2-5] have
since been published. American [2], European [3] and
British [5] respiratory guidelines for the management of
chronic unexplained cough in adults advocate empirical
treatment of gastroesophageal reflux disease (GORD)
with a variety of medications including proton pump
inhibitors (PPIs). In contrast, guidelines from some
national gastroenterological societies are less definitive
about the association between cough and GORD [6-9]
Paediatric cough guidelines do not favour the empirical
approach in adults because GORD as a cause of isolated
cough is rare in children [10,11]. Is there evidence for a
true difference or do these differences exist because opin-
ion leaders in their respective fields have different views?
In this commentary, important limitations in understand-
ing the association between cough and GORD are
explored.
That cough and GORD commonly coexist is indisputable
in both children [12] and adults [13]. The questions of
whether this is 'cause and effect' [14], 'whether GORD
causes cough or vice versa' [15] and 'how commonly can
the symptom of cough be attributed to GORD' remain
controversial [9,16]. Nevertheless the problem is real; in
the community the burden of cough and GORD, in isola-
tion or in combination, is high. Chronic cough is associ-
ated with significant morbidity [17] and the economic
cost in terms of medications alone, is billions of dollars
[18]. Empirical acid antisecretory treatment of cough in
adults adds to this cost. In Australia alone, where the costs
of medications are heavily subsided by the government,
three PPIs are in the top 10 drugs by cost [19]. In 2006
these 3 PPIs alone costs the Australian tax payers almost
A$42.5 million [19].
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Cough and reflux: two common symptoms, 
chance occurrence and which came first?
In many developed countries, cough is the most common
symptom presenting to doctors [18,20]. Chronic cough
can affect up to 20% of the population [21] whilst the
prevalence of GORD in Western populations is up to 25%
[22]. Thus the upper limit of probability of a chance asso-
ciation as independent events is 5% of the population. In
selected patient cohort studies the higher prevalence of
these symptoms would increase the likelihood of a chance
occurrence. That is, in a cohort study of subjects with
chronic cough, the chance occurrence of GORD as an
independent event may be up to 25%.
Not only is it possible that two common symptoms may
coexist merely by chance but determining which symp-
tom came first is difficult and opinions vary. Acutely,
cough can precipitate reflux events as shown objectively
by Paterson and Murat [23] with cough bursts defined on
oesophageal manometry. Using ambulatory pressure-pH-
impedance monitoring, Sifrim and colleagues reported
that the majority (69.4%) of cough events in subjects with
chronic cough, were considered independent of reflux,
whereas 30.6% occurred within two minutes of a reflux
episode [24]. In a review using strict definitions, Dent and
colleagues found that "in the year following the diagnosis
of GORD, patients were at increased risk of a first time
diagnosis of cough (OR 1.7, 95% CI 1.4–2.1), angina (OR
3.2, 95% CI 2.1–4.9), gall bladder disease (OR 3.7, 95%
CI 2.1–6.7), sinusitis (OR 1.6, 95% CI 1.2–2.0) and chest
pain (OR 2.3, 95% CI 1.8–2.8) [25]. However, despite the
reported frequency of assumed cough from GORD and
the common clinical observation that treatment for
GORD may lead to resolution of cough, at least in some
people [26,27] there is glaring lack of published ran-
domised trials [28].
Differences between respiratory and 
gastroenterology society publications
There is a degree of variance between adult respiratory and
gastroenterological society guidelines when considering a
possible association between airway symptoms and
GORD. While gastroenterological society publications
have been more cautious in linking upper airway symp-
toms to GORD [6-9,29], adult respiratory ones largely
endorse the cause and effect [5,30]. Recent gastroenterol-
ogy society recommendations are based largely on system-
atic reviews and meta-analysis [9,31]. In contrast, the
latest published cough guideline [5] omitted meta-analy-
sis data [27,28] which had similar findings to the
approach adopted by gastroenterology societies [6-9,29].
Defining GORD- the changing goal posts
Reflux of gastric contents into the oesophagus can be
acidic, weakly acidic or weakly alkaline (non acid reflux)
and includes 'volume' reflux. Prior to the description of
non-acid or weakly acidic reflux, proponents that cough is
commonly caused by GORD have described that almost
all (>75%) cough (if not all) was associated with acidifi-
cation of the oesophagus and/or resolved with acid sup-
pression therapy [32-34]. However, non-acid reflux can
now be measured using multi-channel intraluminal
impedance combined with pH monitoring and has been
shown to be associated with an undefined but significant
proportion of GORD associated cough [24]. Indeed, until
the last 12 months pH monitoring for acid reflux was the
recommended standard for defining cough associated
with GORD with published positive and negative predic-
tive values of 89 and 100% respectively [2,3]. However,
the predictive value of pH monitoring has been ques-
tioned even for the diagnosis of GORD itself [35] with no
agreement about the gold standard for the diagnosis of
GORD [6]. Furthermore, while the definition of abnormal
acidification has been largely agreed, with three age
dependent cut-offs [6,8], such definitions for associating
GORD to cough remains indeterminate. The belief in
adult respiratory practice, that cough related to GORD
may occur without any reflux symptoms [5] results in fre-
quent empirical therapy for any patient with chronic
cough with or without GORD symptoms. However, a
recent international consensus statement (The Montreal
Delphi consensus report) following a review of the litera-
ture concluded that unexplained laryngeal and respiratory
symptoms were unlikely to be related to GORD in the
absence of heartburn or regurgitation and that typical
heartburn and regurgitation are highly specific for GORD
[9].
Equipment limitations
Almost all (if not all) commercial pHmetry systems have
a maximum capture or download rate of 0.25 Hz. That is,
data points are recorded once every 4 seconds. The active
respiratory muscle phase of a single cough epoch lasts
0.6–0.8 secs (figure 1) and the glottic closure phase of
cough whereby the greatest intrathoracic pressure is gen-
erated lasts 0.2 secs [36]. Thus an objective study of cough
and reflux would require a capture rate of at least 5 Hz
(one data point every 0.2 secs) to ascertain if cough occurs
before a reflux event. Subjective scoring or event marking
on a commercial system is highly inaccurate as far as tim-
ing is concerned, so it is not possible to know whether a
cough occurs before a pH drop (or vice versa) when data
is captured once every 4 secs. Furthermore, data captured
on synchronised (for example to the nearest second) sep-
arate instruments as opposed to a single time frame will
give erroneous results given that resolution rates has to be
less than the compressive phase of a cough when intratho-
racic pressures peaks up to 300 mmHg [36] as it is the
phase most likely associated with a reflux event. This is
illustrated in figure 1 obtained using a specifically builtCough 2007, 3:4 http://www.coughjournal.com/content/3/1/4
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pHmetry-cough-logger with a capture rate of 10 Hz (ie 10
data points every one sec).
Sifrim and colleagues [24] used manometry and pHmetry
(at a slow capture rate 0.25 Hz) to define the occurrence
of acid reflux to cough (in addition to other data). How-
ever, 'cough' was defined on manometry data and current
manometry labelling of 'cough' has only been partially
validated when compared to how cough loggers are vali-
dated [37,38]. Physiologically, changes seen in oesopha-
geal manometry reflect intra-thoracic changes and thus
events such as sneeze, hiccups, throat-clearing manoeu-
vres would appear similar to coughs, as shown in respira-
tory muscle EMG changes. Thus, it is likely that the
association reported was over-estimated.
Acute vs chronic data: are they related?
In addition to the above, it is unknown if acute effects
related to cough preceding or following a reflux event is
relevant to the management of chronic cough. In view of
equipment limitations, it is not surprising that there are
no publications on this, or any controlled trials. It is bio-
logically possible that cough takes a longer time to resolve
following treatment compared to typical reflux symptoms
if there is up-regulation of cough neuro-pathway [39] that
may take time to re-equilibrate. However in Ours and col-
leagues randomised controlled trial, the 'time to response'
was 2 weeks [26].
Laryngo-pharyngeal reflux (LPR)?
Ear, nose and throat (ENT) diseases and LPR are widely
regarded as a cause of chronic cough related to GORD.
However, all controlled trials to date where subjects were
enrolled from ENT clinics and cough was an outcome
measure have shown that GORD treatment is not effica-
cious when compared to placebo [28]. Two additional
controlled studies since a comprehensive review [16] also
showed that neither PPI nor fundoplication were effica-
Cough preceding a pH drop followed by another cough Figure 1
Cough preceding a pH drop followed by another cough. Recordings from a specifically built pHmetry-cough-logger with a cap-
ture rate of 10 Hz (40 times the commercially available systems). Time scale in hours:mins:secs.Cough 2007, 3:4 http://www.coughjournal.com/content/3/1/4
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cious [40,41]. The former was the largest study involving
GORD therapy with cough as an outcome (n = 145). In
contrast, "uncontrolled studies suggest that 40–100% of
patients who have suspected acid-related ENT symptoms
improve on aggressive anti-reflux therapy" [16].
The way forward?
Consumers and medical practitioners may be content to
resort to a therapeutic trial for at least 3 months in all cases
of chronic unexplained cough, as suggested by some [5].
Despite the apparent convenience of such an approach, it
is not without risk of adverse events [42,43], incurs signif-
icant costs and is contrary to the emerging evidence that
suggests that this strategy will meet with infrequent suc-
cess particularly when cough is not associated with typical
reflux symptoms. The advice of Bourke and Drumm
(when discussing the history of the use of cisapride for
GORD) advocated that guidelines must be multidiscipli-
nary, based on systematic review of published work, and
should explicitly link recommendations to the supporting
evidence, is pertinent despite the excellent safety record of
PPIs [44].
Further study of this relatively common clinical conun-
drum is clearly required. High quality placebo controlled
randomised trials using a combination of objective and
subjective outcomes in both adults and children [28] are
needed. Furthermore, better characterisation of the pre-
dictive value of clinical features and measurable abnor-
malities of GORD associated with cough will result in
better selection of patients for therapeutic trials of PPIs or
other therapies. Moreover, the duration of therapy and
time to response needs to be better defined as advice by
some that treatment for cough associated with reflux can
take up to one year is impractical. Lastly, to accurately and
definitively relate cough to pH change temporally, it may
be necessary to have an instrument with a sufficiently fast
capture, recording rate and response time to allow more
precise data collection, something that is lacking in cur-
rently available commercial pHmetry recorders for studies
relating to cough.
Conclusion
The common co-existence of cough and GORD is well
established. By chance alone the occurrence of these as
independent events may be as high as 5% of the general
population. Ascertaining cause and effect is however more
difficult. Although some patients may have resolution of
chronic cough with therapies for GORD there is still insuf-
ficient evidence to determine whether GORD is a com-
mon cause of chronic cough. A multi-disciplinary
approach involving respiratory physicians, gastroenterol-
ogists and ENT surgeons is required to better define this
association and to promulgate consistent guidelines
based on the best evidence. Until randomised placebo
controlled clinical trials are performed with adequate
power and using adequate instrumentation guidance for
therapy in clinical practice will remain based on sub-opti-
mal evidence and this conundrum will remain unre-
solved.
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